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Abstract 
Background: To overcome infectious diseases, the development of mucosal vaccines would be an effective strat-
egy, since mucosal surfaces are the entry site for most pathogens. In general, protein antigens show inherently poor 
immunogenicity when administered by the mucosal route. Therefore, co-administration of an appropriate mucosal 
adjuvant is required to exert immune responses toward pathogen-derived antigens effectively. However, the devel-
opment of a safe and effective mucosal adjuvant system is still challenging. Although, recent studies reported that 
oligodeoxynucleotides (ODNs) containing immunostimulatory CpG motifs (CpG ODNs) act as potent mucosal adju-
vants and are useful in the formulation of nasal vaccines, there are some disadvantages. For instance, the administra-
tion of phosphorothioate (PS)-modified CpG ODNs can induce adverse systemic effects, such as splenomegaly, in a 
dose-dependent manner. Therefore, a reduced dose of CpG ODN might be crucial when used as vaccine adjuvant for 
clinical purposes. Therefore, we prepared a CpG ODN-loaded cationic liposome, and evaluated its mucosal adjuvant 
activity.
Results: We prepared a CpG ODN-loaded DOTAP/DC-chol liposome that was stable during our experiments, by mix-
ing CpG ODNs and liposomes at an N/P ratio of 4. Further, we demonstrated that the attachment of class B CpG ODN 
to the DOTAP/DC-chol liposomes synergistically enhanced antigen-specific IgA production in the nasal area than 
that induced by CpG ODN and DOTAP/DC-chol liposomes alone. The endpoint titers were more than tenfolds higher 
than that induced by either single CpG ODN or single DOTAP/DC-chol liposomes. Additionally, although serum IgG1 
responses (indicated as a Th2 response) remained unchanged for DOTAP/DC-chol liposomes and CpG ODN-loaded 
DOTAP/DC-chol liposomes, the CpG ODN-loaded DOTAP/DC-chol liposomes synergistically induced the production 
of serum IgG2a (indicated as a Th1 response) than that by the individual liposomes.
Conclusions: We conclude that the advantage of using DOTAP/DC-chol liposome harboring CpG ODN is it induces 
both antigen-specific mucosal IgA responses and balanced Th1/Th2 responses. Therefore, such a combination ena-
bles us to resolve the adverse effects of using CpG ODNs (as a mucosal adjuvant) by reducing the overall dose of CpG 
ODNs. Further, the biodegradable and essentially non-antigenic nature of the liposomes makes it superior than the 
other existing mucosal adjuvants.
Keywords: Mucosal adjuvant, Cationic liposome, CpG ODN, Intranasal immunization, Vaccine
© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Open Access
BMC Research Notes
*Correspondence:  rui.tada@gmail.com; aramaki@toyaku.ac.jp 
1 Department of Drug Delivery and Molecular Biopharmaceutics, School 
of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432-1, 
Horinouchi, Hachioji, Tokyo 192-0392, Japan
Full list of author information is available at the end of the article
Page 2 of 9Tada et al. BMC Res Notes  (2017) 10:68 
Background
Infections are one of the most significant risk factors 
for human lives and the second leading cause of death 
worldwide [1, 2]. Much focus has been on intranasal 
mucosal vaccines due to their capacity to elicit immune 
responses at the site pathogen entry and systemic infec-
tion [3–9]. Therefore, mucosal vaccines would be an 
effective strategy to fight infectious diseases caused by 
pathogenic microbes invading through mucosal tis-
sues of host including fungi, bacteria, and viruses. How-
ever, when administrated by the mucosal route, protein 
antigens show inherently poor immunogenicity [10]. 
Therefore, co-administration of an appropriate mucosal 
adjuvant with protein antigens is needed to exert immune 
responses to the antigens effectively [8]. Yet, adjuvants 
used experimentally for a long time are mainly pathogen-
derived toxins, such as the cholera toxin and heat-labile 
enterotoxin, evokes unexpected side effects caused by 
their toxicity and antigenicity [11, 12]. In this context, the 
development of safe and effective mucosal adjuvants is 
fundamental to prevent infections by the use of mucosal 
vaccines in the clinic.
Recent studies reported that intranasal administration 
of synthetic oligodeoxynucleotides (ODNs) containing 
immunostimulatory CpG motifs (CpG ODNs) act as a 
mucosal adjuvant via the recognition by toll-like receptor 
9 (TLR9) in mice. CpG ODN are classified into 5 classes 
based on their specific sequences and effects, namely 
class A, B, C, P, and S. Class B CpG ODN exhibits strong 
B cell activation resulting in enhanced antibody produc-
tion [11, 13–20]. However, there are some disadvantages 
with the use of CpG ODN as adjuvants as it is quickly 
eliminated by host nucleases present in tissues and blood 
under physiological conditions. To prevent CpG ODN 
degradation in the host body, the phosphodiester (PO) 
backbone within CpG ODNs is chemically modified to 
the phosphorothioate (PS) linkage, reducing the sensitiv-
ity of CpG ODN to nuclease digestion, and thus increas-
ing its adjuvant activities [21–24]. Despite the chemical 
modification to improve CpG ODN stability in the host, 
free CpG ODN still has the following disadvantages: (1) 
a reduced affinity to TLR9 for PS-modified CpG ODN 
compared to original CpG ODN [25], (2) The administra-
tion of CpG ODN in mice resulted in splenomegaly in a 
sequence-specific and dose-dependent manner [26], (3) 
PS–modified CpG ODNs are still susceptible to nuclease 
[21], (4) PS-modified CpG ODN transiently activates the 
host complement system, that could lead to cardiovascu-
lar collapse and death [27, 28]. Consequently, a reduced 
dose of PO-modified CpG ODNs with stable form might 
be required for the usage as a safe and efficient mucosal 
adjuvant.
We have recently reported that intranasal adminis-
tration of an antigen with the cationic liposomes com-
posed of 1,2-dioleoyl-3-trimethylammonium-propane 
(DOTAP) and 3β-[N-(N′,N′-dimethylaminoethane)-
carbamoyl] (DC-chol) induced antigen-specific mucosal 
and systemic antibody responses in mice. We further 
revealed that this cationic liposome possesses Th2-type 
adjuvant activities. However, the effects of nasal IgA 
production and Th1-type of immune responses are rela-
tively weak compared with those of the cholera toxin, a 
well-known potent experimental mucosal adjuvant [29]. 
We hypothesized that the combination of CpG ODN 
and the cationic liposomes would exert a more efficient 
IgA response in the nasal area and a Th1-type immune 
response in the systemic system.
To develop a potent mucosal adjuvant system with cati-
onic liposomes, we prepared a class B CpG ODN-loaded 
cationic liposome not only to enhance IgA production in 
mucosal tissues and induce Th1-type immune response 
due to IgG2a production, but also to reduce the overall 
dose of CpG ODNs without any loss of mucosal adju-
vant properties. Subsequently, we evaluated the activities 
of the mucosal adjuvant when administered intranasally 
with ovalbumin as a model antigen, and examined the 
induction of OVA-specific antibody production in both 
mucosal and systemic in mice.
Methods
Animals and materials
Female BALB/c mice (6-weeks old) were purchased from 
Japan SLC (Shizuoka, Japan). The mice were housed 
in a specific pathogen-free environment. All animal 
experiments followed the guidelines for laboratory ani-
mal experiments of the Tokyo University of Pharmacy 
and Life Sciences, and each experimental protocol was 
approved by the Committee for Laboratory Animal 
Experiments at the institution (P14–32 and P15–33). 
DOTAP and DC-chol were purchased from Avanti 
Polar Lipids (Alabama, USA). Class B CpG ODN 1826 
(5′-tccatgacgttcctgacgtt-3′; small letters indicate phos-
phorothioate linkage, underlining indicates the CpG 
motif ) was synthesized by the Hokkaido System Science 
Co., Ltd. (Hokkaido, Japan). Ovalbumin from egg white 
(OVA) was obtained from Sigma-Aldrich (St. Louis, 
USA).
Preparation of the cationic liposomes
Liposomes were prepared as described previously [29, 
30]. Briefly, 10  μmol of total lipids (DOTAP:DC-chol at 
1:1 mol ratios) were evaporated to dryness in a glass tube 
and desiccated for at least 1  h in vacuo. The obtained 
lipid films were hydrated by the addition of 250  μl of 
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phosphate-buffered saline (PBS) and then vortexed at 
room temperature (RT) for 5 min. The multilamellar vesi-
cles were extruded 10 times passing through a 100 nm-
pore polycarbonate membrane (ADVANTEC, Tokyo, 
Japan) and sterilized by 0.45  μm of filter membranes 
(IWAKI, Tokyo, Japan). The particle size and ζ-potential 
of the liposomes prepared in this study were measured by 
NICOMP 380 ZLS (Particle Sizing Systems; Port Richey, 
USA).
Preparation of CpG ODN‑loaded DOTAP/DC‑chol liposomes
One microgram of CpG ODN solution was added into 
the prepared DOTAP/DC-chol liposomes described 
above (10  μl of PBS), and incubated for 5  min at RT. 
After incubation, the samples were ready to use for the 
measurement of their particle size and ζ-potential stated 
above, and assessment of their mucosal adjuvant activi-
ties described below.
Agarose gel retardation assay
CpG ODN-loaded DOTAP/DC-chol liposomes were pre-
pared by combining CpG ODN and DOTAP/DC-chol 
liposomes for 5  min at RT. The complex formation was 
determined by an agarose gel retardation assay. Com-
plexes and free CpG ODN at various N/P ratio were 
applied onto 1% agarose gels. The agarose gels were 
stained and visualized with the GelRed nucleic acid gel 
stain (Wako Pure Chemical Industries).
Immunization and sampling schedule
Mice were divided into five groups and nasally immu-
nized as follows: (1) PBS, (2) OVA alone, (3) OVA plus 
DOTAP/DC-chol liposomes, (4) OVA plus CpG ODN, 
or (5) OVA plus CpG-liposomes (N/P ratio  =  4). Each 
group of mice was immunized once a week. To obtain 
serum samples, blood samples were collected. The blood 
was allowed to clot at 25 °C for 30 min followed by 4 °C 
for 60 min and then the serum was separated by centrif-
ugation at 1200g for 30  min and stored at −80  °C until 
ELISA assays. Nasal wash fluid samples were collected 
using 200 µl of PBS solution as described earlier [29, 31, 
32].
ELISA for detecting OVA‑specific antibody production [29]
A 96-well Nunc MaxiSorp plate (Thermo Scientific, 
MA, USA) was coated with 1.25 μg of OVA in 0.1 M car-
bonate buffer (pH 9.5) and incubated overnight at 4  °C. 
The plate was then washed with PBS containing 0.05% 
Tween 20 (PBST) and blocked with 1% bovine serum 
albumin (BSA; Wako Pure Chemical Industries) con-
taining PBST (BPBST) at 37 °C for 60 min. The plate was 
washed and incubated with serum samples for 60  min 
at 37  °C. It was then washed with PBST, treated with 
peroxidase-conjugated anti-mouse IgA, IgG, IgG1, or 
IgG2a secondary antibody (SouthernBiotech, Alabama, 
USA) in BPBST, and developed using a tetramethylben-
zidine (TMB) substrate system (KPL, Maryland, USA). 
Color development was terminated using 1 N phosphoric 
acid, and the optical density was measured at 450  nm 
with 650 nm of reference.
Statistical analysis
Statistical differences were assessed by Kruskal–Wallis 
with Dunn’s post hoc test. p values less than 0.05 were 
considered significant.
Results and discussion
Characterization of CpG ODN‑loaded DOTAP/DC‑chol 
liposomes
First, loading capacity of DOTAP/DC-chol liposome with 
class B CpG ODN in PBS solution was evaluated by an 
agarose gel retardation assay. The liposome/CpG ODN 
ratio was expressed as the N/P ratio that was dependent 
on the ratio of nitrogen (N) in the liposomal lipids to the 
phosphates (P) in the nucleic acids of CpG ODNs. At the 
N/P ratio of 3, we still observed free CpG ODN that was 
not complexed with the liposomes. Then at the N/P ratio 
of 4, free CpG ODN could not be detected, indicating all 
CpG ODN was loaded onto the liposomes in this N/P 
ratio (Fig.  1). In case of higher N/P ratios, DNA loaded 
onto nanoparticles can be easily detected on the agarose 
gel owing to retention of the complex within the wells. 
However, the retained DNA cannot be visualized in the 
gel image shown in Fig. 1 because DNA complexed with 
nanoparticles diffuses into the staining buffer during the 
staining process, thus hampering visualization. In addi-
tion to the agarose gel retardation assay, particle size and 
ζ-potential analyses of the CpG ODN-loaded DOTAP/
DC-chol liposomes at various N/P ratios were con-
ducted (Fig.  2). The DOTAP/DC-chol liposomes alone 
in PBS solution were positively charged (3.6 ± 2.3 mV). 
Increasing quantities of CpG ODN led to a reduction in 
this positive charge of DOTAP/DC-chol liposomes until 
an N/P ratio of 4. Subsequently, continuous increase in 
the N/P ratio (increase in the liposome quantity) leads to 
rise in the average ζ-potential as we tested in the present 
study (up to N/P ratio of 24). Collectively, the N/P ratio 
of 4 seemed that CpG ODN at the surface of DOTAP/
DC-chol liposomes was saturated. Additionally, the CpG 
ODN-loaded DOTAP/DC-chol liposomes were stable 
at an N/P ratio of 4 during course of experiments, how-
ever with an increased N/P ratio they became unstable in 
terms of their particle size, possibly due to their positively 
charged ζ-potential (data not shown). Therefore, we here-
after examined mucosal adjuvant effects of CpG ODN-
loaded DOTAP/DC-chol liposomes at the N/P ratio of 
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4. At this N/P ratio, CpG ODN-loaded DOTAP/DC-chol 
liposomes had a particle size of 124.2 ± 53.3 nm with a 
ζ-potential of −3.9 ± 4.7 mV (Table 1). It is noteworthy 
that the distribution of number-based particle size of 
CpG ODN-loaded DOTAP/DC-chol liposomes at an N/P 
ratio of 4 showed almost narrow distribution. In contrast, 
distribution of particle size appeared broader when the 
N/P ratio was increased, indicating that the nanoparticles 
were aggregated (data not shown). These sizes, at the N/P 
ratio of 4, would be suitable, since a possible mechanism 
underlying the advantage of CpG ODN attached to a 
nanoparticle-like liposome could be an efficient delivery 
to antigen-presenting cells (APCs) such as dendritic and 
B cells [33, 34]. APCs are able to take up the nano-sized 
Fig. 1 Agarose gel retardation assay of the prepared CpG ODN-loaded DOTAP/DC-chol liposomes with various N/P ratios. The prepared CpG ODN-
loaded DOTAP/DC-chol liposomes were loaded onto a 2% agarose gel and then ODN bands were visualized by staining with GelRed Nucleic Acid 
Gel Stain
Fig. 2 Distribution of particle size (a) and ζ-potential (b) of the prepared CpG ODN-loaded DOTAP/DC-chol liposomes with various N/P ratios. The 
particle size and ζ-potential of the prepared CpG ODN-loaded DOTAP/DC-chol liposomes were measured by NICOMP 380 ZLS. The particle size and 
ζ-potential are expressed as the mean ± standard error for samples assayed in triplicate
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particles efficiently [35]. We have already reported that 
DOTAP/DC-chol liposomes are preferentially uptaken 
by DCs in vivo [29].  
Antigen‑specific nasal IgA and serum IgG responses 
after administration of OVA with class B CpG ODN
We next investigated a required dose of class B CpG 
ODN to exhibit the mucosal adjuvant effects when intra-
nasally administrated with OVA in BALB/c mice. As 
shown in Fig.  3, intranasal treatment of 10  µg of CpG 
ODN exerted the production of nasal IgA (endpoint titer 
with median value; 44.3); however, intranasal administra-
tion of 1 µg of CpG ODN did not induce any nasal IgA 
production. Meanwhile, serum IgG levels of mice that 
received all dose ranges of CpG ODN examined in this 
study did not show any differences.
Induction of antigen‑specific nasal IgA and serum IgG 
after administration of OVA with CpG ODN‑loaded DOTAP/
DC‑chol liposomes
To evaluate the impact of CpG ODN attached to the cati-
onic liposomes, DOTAP/DC-chol liposomes, we next 
examined whether the augmentation of the mucosal 
adjuvant activities of CpG ODN-loaded DOTAP/DC-
chol liposomes could be observed compared with those 
of CpG ODN alone. Namely, we explored the mucosal 
adjuvant activities of CpG ODN-loaded DOTAP/DC-
chol liposomes at the N/P ratio of 4. In case of IgA induc-
tion in the nasal area, 1 µg of CpG ODN-loaded DOTAP/
DC-chol liposomes synergistically induced IgA produc-
tion (endpoint titer with median value; 738.8). These val-
ues are more than 10 times higher than those induced 
by free CpG ODN. Interestingly, the DOTAP/DC-chol 
Table 1 Physicochemical properties of the CpG ODN-loaded DOTAP/DC-chol liposomes used in this study
N/P ratio Particle size (nm) ζ‑potential (mV)
CpG ODN-loaded DOTAP/DC-chol liposome 0 137.9 ± 11.6 4.0 ± 2.1
DOTAP/DC-chol liposome 4 124.2 ± 53.3 −3.9 ± 4.7
Fig. 3 Mucosal adjuvant activity of CpG ODN assessed by the induction of OVA-specific nasal IgA and serum IgG in BALB/c mice. BALB/c female 
mice were immunized intranasally with OVA (5 µg/mouse) alone, or OVA (5 µg/mouse) plus CpG ODN (1 or 10 µg/mouse) on days 0 and 7. Serum 
and nasal washes were collected on day 14. The anti-OVA IgA level in nasal washes and anti-OVA IgG, IgG1, and IgG2a levels in serum were detected 
by ELISA assay as described in the “Methods” section. The data were obtained from three independent experiments. The box-plot shows the median 
value with the 25th–75th percentiles and the error bars indicate the 5th–95th percentiles. Symbols in the box plots represent individual mice (PBS, 
n = 8; OVA, n = 8; OVA plus CpG ODN (1 µg/mouse), n = 8; OVA plus CpG ODN (10 µg/mouse), n = 4). Significance was assessed using the Kruskal–
Wallis with Dunn’s post-hoc test: *p < 0.05, NS not significant
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liposomes did not induce any antigen-specific IgA 
responses in the nasal area at the dose used (8.52 nmol/
mouse), which is similar to our previous study [29]. In 
contrast to IgA production, the antigen-specific IgG 
responses did not change even when CpG ODN was 
loaded onto the liposomes as DOTAP/DC-chol liposome 
alone strongly induces antigen-specific IgG production 
(Fig. 4). 
Since murine serum IgG subclasses have been used to 
assess the type of immune responses [36, 37], we inves-
tigated the production of serum IgG1 and IgG2a after 
intranasal immunization with OVA and CpG ODN-
loaded DOTAP/DC-chol liposomes. Our results (Fig. 5) 
reveal that serum IgG1 responses remained unchanged 
for both DOTAP/DC-chol liposomes and CpG ODN-
loaded DOTAP/DC-chol liposomes, indicating that 
serum IgG1 responses (referred to as Th2 response) 
largely relied on the DOTAP/DC-chol liposomes, which 
act as a Th2-type immune adjuvant by inducing a Th2 
cytokine, interleukin-4 (IL-4) [29]. For serum IgG2a 
responses, the CpG ODN-loaded DOTAP/DC-chol 
liposomes synergistically induced the production of 
serum IgG2a (indicated as a Th1 response), which largely 
depended on the effect of CpG ODN. CpG ODNs are 
known to strongly induce Th1-associated cytokines, such 
as interferon-γ (IFN-γ) and interleukin-12 (IL-12) from 
natural killer cells (NKs) and macrophages, respectively 
[14]. These cytokines mainly promote cellular immunity 
also referred to as Th1 response. In this study, the sam-
ples for the determination of antibody production were 
collected on day 14. Generally, on day 14, post initial 
immunization, antibody responses do not reach maxi-
mum levels because of exposure only to primary antigen. 
In such cases, maximum antibody production would nor-
mally take about 30  days post exposure to the antigen. 
Furthermore, the peak of hypermutated high-affinity 
IgG antibodies generated via the germinal center reac-
tion is reached 4–6  weeks post exposure. In this study, 
mice were administered the antigen with mucosal adju-
vant twice: the first dose followed by a booster dose. It is 
well demonstrated that booster exposure to the antigen, 
in secondary immune responses, reactivates immune 
memory and results in a rapid increase of antibody 
titers (typically reaching maximum antibody response 
within 7  days) [38, 39]. Therefore, the immunization 
schedule used in this study was ideal for the compari-
son of the mucosal adjuvant activity between different 
sets of adjuvants. The results obtained here indicate that 
Fig. 4 Mucosal adjuvant activity of CpG ODN-loaded DOTAP/DC-chol liposomes assessed by the induction of OVA-specific nasal IgA and serum 
IgG in BALB/c mice. BALB/c female mice were immunized intranasally with PBS, OVA (5 µg/mouse) alone, OVA (5 µg/mouse) plus DOTAP/DC-chol 
liposomes, OVA (5 µg/mouse) plus CpG ODN (1 µg/mouse), or OVA (5 µg/mouse) plus CpG ODN-loaded DOTAP/DC-chol liposomes on days 0 and 
7. Serum and nasal washes were collected on day 14. The anti-OVA IgA level in nasal washes and anti-OVA IgG, IgG1, and IgG2a levels in serum were 
detected by ELISA assay as described in the “Methods” section. The data were obtained from three independent experiments. The box-plot shows 
the median value with the 25th–75th percentiles and the error bars indicate the 5th–95th percentiles. The symbols in box plots represent individual 
mice (PBS, n = 10; OVA, n = 10; OVA plus liposome, n = 10; OVA plus CpG-loaded liposome, n = 12). Significance was assessed using the Kruskal–
Wallis with Dunn’s post–hoc test: *p < 0.05, NS not significant
Page 7 of 9Tada et al. BMC Res Notes  (2017) 10:68 
the combination of CpG ODN and DOTAP/DC-chol 
liposomes exert balanced Th1/Th2 immune responses, 
suggesting that CpG ODN-loaded DOTAP/DC-chol 
liposomes can act as a nanoparticle-based mucosal adju-
vant system. The detailed mechanism(s) responsible 
for the effective induction of antigen-specific mucosal 
immune responses by CpG ODN-loaded DOTAP/DC-
chol liposomes remain ambiguous. It is possibly caused 
by a more efficient delivery of both CpG ODN and OVA 
to the APCs by DOTAP/DC-chol liposomes. In an ear-
lier study, we have already reported that the DOTAP/
DC-chol liposomes promote antigen-uptake by APCs 
in  vivo [29]. Additionally, recent reports have revealed 
that the combination of multiple adjuvants synergisti-
cally stimulated APCs [40], therefore we hypothesized 
that DOTAP/DC-chol liposomes can induce endog-
enous immunostimulatory molecules in the nasal area, 
such as adenosine triphosphate (ATP), high mobility 
group box–1 (HMGB1), and host double stranded DNA 
that are considered as an damage-associated molecular 
pattern (DAMP) to trigger an innate immune response. 
Therefore, we are now investigating whether the cationic 
liposomes exhibit host genomic DNA in the nasal area 
when administrated intranasally.
Taken together, CpG ODN-loaded DOTAP/DC-chol 
liposomes demonstrated higher mucosal adjuvant activ-
ity than free CpG ODN and induced of balanced Th1/Th2 
reactions.
Conclusions
In the present study, we showed that intranasal immu-
nization of a model antigen, OVA, with class B CpG 
ODN-loaded DOTAP/DC-chol liposomes synergistically 
induced both antigen-specific mucosal IgA and systemic 
IgG responses in mice, clearly demonstrating that the 
attachment of CpG ODN onto the cationic liposomes 
remarkably enhanced mucosal adjuvant effects. These 
aspects allow us to reduce the dose of CpG ODN in nasal 
vaccines. Vaccine system using liposomes have advan-
tages because liposomes are biodegradable within host 
and are essentially non-antigenic. Moreover, liposomal 
vehicle is easily able to deliver to the intended tissues 
and/or cells by modifying their liposomal surface with 
proteins or carbohydrates. These characteristics are 
believed to be superior to that of the existing mucosal 
adjuvants. However, the underlying mechanisms involved 
in the effect of the mucosal adjuvant are not yet fully 
understood, the potent mucosal adjuvant activity of CpG 
ODN-loaded DOTAP/DC-chol liposomes might help in 
developing an appropriate strategy for mucosal vaccine 
therapy to prevent and treat infectious diseases.
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